Bone grafting for dental implants: five materials, three real indications, and the marketing problem inside the procedure

The patient came in two weeks ago with a 14-page treatment plan from a Mexican clinic. Two implants in the posterior maxilla; bilateral sinus lifts; bilateral lateral ridge augmentations; a particulate xenograft mixed with platelet-rich fibrin; a non-resorbable titanium-reinforced membrane on each side; rhBMP-2 sponge supplementation. Six-month healing. Then four-month healing after fixture placement. Total quoted at $11,400 USD before any prosthetics. She wanted to know whether everything in the plan was necessary.

Most of it was not. A short implant on each side, no graft, single-visit placement, eight-week healing to a screw-retained zirconia crown would have been a defensible alternative protocol with strong evidence behind it. The graft-heavy plan was not malpractice. It was a maximalist version of a procedure that has a much smaller and more selective version available, and the price of the maximalist version was three to four times the price of the alternative. The patient was being offered the procedure the clinic preferred to sell, not the procedure the clinical case required.

This piece picks up where the upstream review on whether the implant case in front of you needs a graft at all leaves off. That piece argued that the majority of bone-graft recommendations in cosmetic and high-volume international markets are for cases where short implants, tilted implants, or zygomatic implants would have eliminated the need for grafting entirely. This piece is for the cases where a graft is genuinely indicated, where the question becomes: which material, in what configuration, and against which alternative augmentation strategy.

Five materials are in routine use. The differences between them are real, the cost ranges are wide, and the marketing inside the graft category itself runs in the same direction as the marketing around the procedure. The clinic that sells the most expensive graft as the only acceptable graft is not always wrong, but the patient is usually not in a position to tell.

The three indications where a graft is genuinely the right answer

Before the material question, the indication question. In current 2026 practice, the three case profiles for which a bone augmentation procedure is well-supported by the evidence are these.

Lateral ridge defect of less than 4 mm width at the planned implant site, in a non-bruxer with a stable bite and adequate vertical bone height. A horizontally deficient ridge that cannot host a 3.5 mm or wider implant without dehiscence or fenestration is a defensible indication for lateral augmentation. The 2015 Sanz-Sánchez et al. systematic review found that staged lateral ridge augmentation produced predictable implant survival outcomes (over 95 percent at five years) when the residual horizontal bone width was less than 4 mm pre-graft and the case was properly worked up.https://pubmed.ncbi.nlm.nih.gov/26124217/ The qualifier matters: predictable means the graft consolidated and the implant survived, not that the graft was necessary in every case offered it.

Vertical bone height less than 5 mm in the posterior maxilla, with planned single implants in the molar region, in a patient who has been informed of the short-implant alternative. A sinus lift is correctly indicated when the residual subantral bone is insufficient to host any commercially available implant. The 2008 Pjetursson et al. systematic review reported five-year implant survival in the 90 to 95 percent range for implants placed in sinus-augmented sites, depending on graft material and surgical approach.https://pubmed.ncbi.nlm.nih.gov/18724842/ The implant survival figures are good. They are not as good as native-bone implant placement in the same patient, which is one of several reasons to ask whether the sinus lift was the only option in the first place.

Anterior aesthetic zone with documented buccal plate deficiency where an immediate or delayed implant is planned and the gingival architecture cannot otherwise be preserved. This is the indication where the cosmetic justification is the strongest because the visible soft tissue contour at the gingival margin depends on the underlying bone profile. A guided bone regeneration procedure with a slow-resorbing material under a barrier membrane is well-supported in this setting.

That is the list. Three indications, all with bone-volume thresholds, all with patient-selection caveats, all with viable alternatives in a subset of cases. The 2016 Aghaloo et al. Consensus Conference Proceedings document the evidence base in detail and are the authoritative reference I use when working up these cases.https://pubmed.ncbi.nlm.nih.gov/27228203/

If the indication in the plan in front of you is not one of these three and the alternatives have not been ruled out in writing, the question is not which graft material to use. The question is whether the graft is the right procedure at all.

The five materials, briefly

There are five categories of graft material in routine 2026 use for dental implant augmentation.https://en.wikipedia.org/wiki/Bone_grafting

Autograft. The patient’s own bone, harvested from an intraoral or extraoral donor site. The intraoral donors are the mandibular ramus, the mandibular symphysis (chin), and the maxillary tuberosity. The extraoral donor for large reconstructive cases is the iliac crest (hip), though this is rare in routine implant dentistry. Autograft is osteogenic (contains living cells that form bone), osteoinductive (contains growth factors that recruit additional bone-forming cells), and osteoconductive (provides a scaffold for new bone growth). It is the historical gold standard.

Allograft. Bone from a human cadaver donor, processed, sterilised, and freeze-dried or demineralised. Commercially supplied as particulate, block, or putty formats. Allograft is osteoconductive and partially osteoinductive depending on processing. The most common formats are demineralised freeze-dried bone allograft (DFDBA) and mineralised freeze-dried bone allograft (FDBA).

Xenograft. Bone from a non-human source, almost always bovine, processed to remove organic material and leave the mineral matrix. The dominant commercial product is Bio-Oss (Geistlich). Xenograft is osteoconductive only. It resorbs very slowly (some xenograft particles persist at the graft site at decade-long follow-up) and is favoured for cases where long-term volume maintenance matters more than rapid bone turnover.

Alloplast. Synthetic graft material. Calcium phosphate ceramics (hydroxyapatite, beta-tricalcium phosphate), bioactive glass, calcium sulphate, and polymer scaffolds are the main alloplast categories. Most are osteoconductive only. Some newer alloplasts incorporate growth factors or are designed for controlled resorption rates.

Growth-factor adjuncts. Not graft materials in themselves but biologics added to a graft to enhance bone formation. The two most commonly marketed are platelet-rich fibrin (PRF, autologous, prepared from a patient blood draw chairside) and recombinant human bone morphogenetic protein-2 (rhBMP-2, supplied commercially in a collagen carrier under the brand Infuse). Both have specific indications and significant cost implications.

When autograft is the right answer

Autograft has not been displaced by the commercial alternatives as much as the marketing implies. It remains the clinically correct choice in specific situations.

Large-volume vertical augmentation in atrophic mandibles or maxillae. When the graft has to span a significant defect (vertical augmentation of more than 4 mm, or block grafting for a large lateral defect), autograft block from the ramus or symphysis remains the most predictable choice. The biology is unambiguous: living bone with intact growth factors integrates faster and more reliably than processed substitutes. The trade-off is donor-site morbidity, a separate surgical procedure, longer operative time, and a small but real risk of paresthesia at the donor site, particularly with mandibular symphysis harvest.

Cases where graft integration speed matters more than long-term volume. A patient on a tight timeline (a single international trip, for instance) who has a defect requiring a graft is poorly served by a slow-integrating xenograft that will not consolidate for six months and may not be ready for fixture placement at the four-month mark. Autograft is faster.

Patients who decline allograft on religious or personal grounds. This is not a clinical indication, but it is a real consideration. Some patients will not accept cadaveric tissue. Some will not accept bovine tissue. For those patients, autograft is the option that respects the constraint.

The reason autograft has lost market share to allograft and xenograft is not that it has been disproven. It is that the commercial alternatives are easier to bill for, faster to place, and avoid the second surgical site. The clinical question of whether the case in front of the clinician would actually do better with autograft is not always the question the clinician asks. The 2016 Aghaloo et al. consensus document is explicit that autograft remains the reference standard for vertical augmentation and large lateral defects.https://pubmed.ncbi.nlm.nih.gov/27228203/

When allograft is the right answer

Allograft is the clinically appropriate choice for a meaningful subset of cases and is the most-used category in 2026 North American implant dentistry, with significant penetration in Australia and Europe.

Intermediate-size lateral ridge augmentation where autograft donor-site morbidity is not justified by the defect size. A lateral defect of 2 to 4 mm in a patient who does not want a chin or ramus harvest is a defensible allograft indication. The integration is slower than autograft and faster than xenograft. The volume maintenance is intermediate.

Socket preservation grafting at the time of tooth extraction. A patient who has an extraction planned and an implant planned for the same site within 4 to 6 months is well-served by an allograft socket preservation graft (DFDBA or FDBA) under a resorbable membrane. This is the highest-volume single indication for allograft in routine practice.

Cases where the clinician has a documented preference for allograft handling characteristics and has the surgical training to use it well. This is a real clinical variable. Some clinicians achieve better consolidation outcomes with allograft than with xenograft in their own hands. Material selection in surgery is partly about what the surgeon can use well.

Allograft is supplied by tissue banks. In Australia, the donor source, the processing standards, and the chain-of-custody are tightly regulated. In some international markets the same regulatory rigour does not apply, and a patient receiving an allograft in a less-regulated jurisdiction should ask which tissue bank supplied the material and what the donor-screening protocol was. This is a legitimate patient-safety question, not an unfounded concern.

When xenograft is the right answer

Xenograft, particularly Bio-Oss, has become the default graft material in much of European, Australian, and high-volume international implant dentistry, including in the cosmetic Turkish, Hungarian, Mexican, and Vietnamese markets. The default status is not entirely unearned, and is not entirely earned either.

Sinus lift augmentation in cases where long-term volume maintenance is the primary goal. Xenograft is osteoconductive and very slow to resorb. In the sinus, where the augmented bone supports an implant that will load for decades, slow resorption and long-term volume maintenance are clinically desirable. The 2008 Pjetursson sinus-lift review documented good five-year survival outcomes with Bio-Oss in the sinus indication.https://pubmed.ncbi.nlm.nih.gov/18724842/

Buccal plate preservation in anterior aesthetic-zone cases. The slow resorption of xenograft particles helps maintain the buccal volume that the gingival contour depends on. Some xenograft persists at the site at 10-year follow-up. Whether this is a feature or a defect is contested in the literature.

Combined techniques where a small autograft volume is extended with xenograft as a volume bulker. A common technique in larger lateral augmentations is to harvest a small autograft volume (which provides the biology) and mix it 50:50 with xenograft (which provides the volume and slow resorption). This is the workhorse approach for moderate-to-large lateral defects in academic implant programs.

The case against universal xenograft is that it is osteoconductive only, integrates more slowly than autograft or allograft, and produces a composite tissue at the graft site that is not purely native bone even at long follow-up. For a patient whose case would have done equally well with autograft from a small ramus harvest, paying for a xenograft is paying for a clinical preference, not a clinical necessity. For a patient whose case would have been managed entirely with a short implant and no graft at all, paying for any graft material is paying for the wrong procedure.

Where alloplast belongs

Synthetic graft materials have a narrower set of correct indications than the manufacturer marketing implies.

Small defects where biology is less critical than volume. A small socket preservation graft in a non-aesthetic site, or a small lateral defect in a patient who declines biological materials, can be defensibly managed with beta-tricalcium phosphate or hydroxyapatite alloplasts. The integration is acceptable. The aesthetic outcome is less consistent.

Cases where regulatory or supply-chain considerations rule out biological materials. Some jurisdictions and some patient situations rule out cadaveric and animal materials. Alloplasts are the option that remains.

Combined with growth factor adjuncts. Some alloplast scaffolds are designed to carry growth factors (including PRF or rhBMP-2). In specific large reconstructive cases, this combination is defensible.

The 2015 Sanz-Sánchez review found that alloplast materials produced acceptable but generally inferior lateral ridge augmentation outcomes compared to autograft and biological substitutes.https://pubmed.ncbi.nlm.nih.gov/26124217/ In current practice, alloplast is most often the right answer in the middle of the indication spectrum, not at the high end.

Growth-factor adjuncts: where the marketing diverges sharply from the evidence

Two growth-factor adjuncts are routinely marketed alongside dental implant grafting: platelet-rich fibrin (PRF) and recombinant human bone morphogenetic protein-2 (rhBMP-2). The evidence base for these two is very different.

Platelet-rich fibrin (PRF). Autologous, prepared chairside from a patient blood draw, centrifuged into a fibrin scaffold that contains the patient’s own growth factors. PRF is inexpensive (the cost is essentially the centrifuge time and a blood draw), low-risk (autologous, no allergic potential), and has a reasonable evidence base for modest improvements in soft tissue healing and small graft consolidation. It is a defensible adjunct in most graft cases. It is not transformative.

Recombinant human bone morphogenetic protein-2 (rhBMP-2, Infuse). A commercially manufactured biologic supplied in a collagen sponge carrier. Approved by the FDA for specific oral and maxillofacial indications including sinus floor augmentation and localised alveolar ridge defects associated with extraction sockets. The 2018 Lin et al. systematic review found that rhBMP-2 produced bone volumes comparable to autograft in sinus and ridge augmentation indications, with the trade-offs of significant cost, postoperative swelling that can be substantial, and a specific contraindication in patients with known or suspected malignancy.https://pubmed.ncbi.nlm.nih.gov/30264461/

The marketing problem with rhBMP-2 in high-volume international clinics is that it is routinely added to grafts where the indication is debatable and the cost is significant. A patient with a 4 mm lateral defect in a non-aesthetic site does not, by published evidence, need rhBMP-2. A patient with a complex reconstructive case after trauma or tumour resection may. The clinical question is the indication. The marketing question is the upsell.

If rhBMP-2 has been included in a treatment plan you have received, the question to ask is: what specific clinical feature of my case makes recombinant growth factor supplementation worth the additional cost over a conventional graft? An answer that references the patient’s specific defect geometry, surgical staging, or healing constraints is a clinical answer. An answer that references “the most advanced biologic available” is a marketing answer.

What this looks like in the cosmetic and high-volume international markets

The pattern that runs through this piece is the same pattern this publication has documented at the procedure-level for the implants-do-not-need-grafting question, at the prep-side for the Turkey teeth phenomenon, and at the material-selection level for single-crown zirconia versus PFM. High-volume cosmetic-driven clinics in Turkey, Hungary, Mexico, Vietnam, and parts of the Australian metropolitan cosmetic market are selecting graft materials and adjuncts at the high end of the cost-and-complexity spectrum where the clinical case does not require it.

The structural dynamics are consistent. A xenograft costs more than an alloplast and bills as a more “premium” component of the plan. A xenograft mixed with PRF and topped with a non-resorbable titanium-reinforced membrane bills higher still. Add rhBMP-2 and the line item enters its own category. None of these additions is wrong on its own. All of them are right for some patient. The patient who is being offered all of them, in the first treatment plan, on a case that would have been managed with a short implant and no graft is not being offered a clinically tailored plan. She is being offered the maximalist version that the clinic prefers to sell.

The countervailing evidence: the 2016 Lemos et al. meta-analysis on short implants found that 6 mm implants placed in posterior atrophic jaws produced five-year survival outcomes statistically indistinguishable from longer implants placed in grafted sites.https://pubmed.ncbi.nlm.nih.gov/26878711/ For posterior atrophic cases, the short-implant alternative removes the graft question entirely. For lateral ridge defects under 3 mm, the small-diameter implant alternative is often viable. For sinus cases with 5 to 6 mm of residual bone, transcrestal sinus elevation with osteotomes and no graft (the Summers technique) is viable for many candidates. These alternatives exist, are well-supported in the literature, and are systematically not offered in high-volume international plans that price the graft-heavy version of the procedure.

Cost and source-market context

Approximate cost ranges as of Q2 2026, per site, exclusive of the implant fixture and crown:

• Autograft, intraoral harvest plus particulate graft, single site: Sydney $1,800–3,200 AUD; New York $1,400–2,800 USD; Ho Chi Minh City $400–800 USD; Antalya $300–700 USD; Cancun $700–1,400 USD
• Allograft, particulate, with resorbable collagen membrane: Sydney $1,400–2,400 AUD; New York $1,200–2,000 USD; Ho Chi Minh City $300–600 USD; Antalya $250–500 USD; Cancun $500–1,000 USD
• Xenograft (Bio-Oss), particulate, with resorbable collagen membrane: Sydney $1,600–2,800 AUD; New York $1,300–2,200 USD; Ho Chi Minh City $400–800 USD; Antalya $300–700 USD; Cancun $600–1,200 USD
• Sinus lift, lateral window approach, with xenograft and membrane: Sydney $3,500–6,500 AUD per side; New York $2,800–5,500 USD per side; Ho Chi Minh City $900–1,800 USD per side; Antalya $700–1,500 USD per side; Cancun $1,500–2,800 USD per side
• rhBMP-2 (Infuse) sponge supplementation, per site: Sydney $1,800–3,500 AUD; New York $1,200–2,500 USD; international rhBMP-2 pricing varies widely and the product is sometimes substituted with non-Infuse biologics that should be specified by name in the quote

All figures include the graft material, biologics or membranes, and the surgical procedure but exclude the implant fixture, abutment, and crown. The structural cost differential between domestic and international markets is documented in the implant-cost-by-country reference and in the Australian source-market cost analysis. The differential is real. It does not on its own settle the question of whether the graft was the right procedure. A patient who paid one-quarter of the Sydney price for a sinus lift that a short implant alternative would have eliminated has not saved money. She has spent less on a procedure she did not need.

For the broader source-market context driving Australian patients toward international implant treatment, including the structural reasons private health insurance extras do not close the gap on major implant work, see the long read on the dental care access crisis. For the policy-level companion documenting what happens when international implant cases produce complications that need domestic management, see the cross-border dental liability review for Australian patients.

The falsification condition

I hold the view that bone grafting in dental implant cases is over-indicated in cosmetic-heavy domestic markets and in high-volume international markets, that within the cases where a graft is genuinely indicated the material selection is being driven more by manufacturer marketing and clinic billing than by clinical evidence, and that rhBMP-2 in particular is being added to plans where the clinical indication is weak and the cost contribution is significant.

What evidence would change this view?

If a prospective comparative trial with N greater than 500 per arm and 10-year follow-up showed that xenograft-with-rhBMP-2 in lateral ridge defects produced clinically meaningful improvements in implant survival, peri-implant bone stability, or aesthetic outcomes compared to autograft-only and short-implant-no-graft alternatives in matched cases, the maximalist-plan argument would weaken.

If a prospective short-implant cohort from cases originally planned for graft-and-conventional-implant treatment produced systematically worse five-year outcomes than the graft-and-conventional protocol, the short-implant alternative would no longer be a viable substitute for the indications I currently consider it suitable for.

If a regulated international tissue-bank ecosystem with chain-of-custody documentation comparable to Australian or US standards became routine in the cosmetic dental tourism markets, the patient-safety question on allograft material in those settings would be substantially resolved.

None of these conditions currently obtain. The existing evidence supports a graft-material-selection framework that places autograft, allograft, xenograft, alloplast, and growth-factor adjuncts in different parts of the indication spectrum, with material selection driven by the specific defect geometry, patient factors, and the genuinely available alternatives. The market behaviour does not reflect that framework. The gap between the framework and the marketing is where patients pay for procedures they did not need.

What to ask your clinician

If you have been quoted a bone graft as part of an implant treatment plan, these questions distinguish a clinical recommendation from a billing default.

1. “What is the specific bone-volume measurement at the implant site, and what is the minimum bone volume required to place an implant without grafting?”

This is a numerical question with a numerical answer. The CBCT measurements should be specified in millimetres in three dimensions at the planned implant location. The minimum bone volume for a graft-free implant depends on the implant diameter and length chosen. If the clinician cannot give you these numbers, the case has not been worked up to a level where the graft recommendation is clinically grounded.

2. “What is the short-implant, tilted-implant, or small-diameter implant alternative for my case, and what would have to be true about my anatomy for one of those alternatives to be viable?”

For the posterior maxilla, the short-implant alternative is the most common omission in cosmetic-heavy plans. For full-arch cases, tilted implants and zygomatic implants are the omissions. A clinician who has not considered these alternatives has skipped the upstream question.

3. “Which specific graft material is being recommended, what is its source and brand name, and what is the alternative material that would be defensible in my case?”

The material name matters. “Bone graft” is not a specification; “Bio-Oss particulate xenograft, 0.25-1 mm particle size, 0.5 cc per site” is. If the answer to this question is vague, the plan has not been written up at the level the procedure requires.

4. “Is rhBMP-2 included in the plan, and if so, what specific clinical feature of my case makes it worth the additional cost over a conventional graft?”

For a routine lateral defect or small sinus lift, the answer should be that rhBMP-2 is not indicated. If it is included anyway, the indication should be specific (large reconstructive defect, failed prior graft, specific anatomical constraint) and the clinical justification should be in writing.

5. “What is the alternative protocol if I decline the graft component of this plan?”

A clinician with a robust treatment plan can describe the alternative. A clinician who answers “we cannot place the implant without the graft” without offering the short-implant or tilted-implant alternative has not engaged with the question.

These questions are not adversarial. A competent clinician will welcome them. The answers tell you whether the plan you have received reflects the published evidence on bone augmentation material selection, or the convenience of the more profitable line item.

For the upstream question (whether the graft was the right procedure in the first place, given the alternatives) the why most dental implants do not need grafting review sits one decision earlier in the same clinical hierarchy. For the procedure-level companion on what a defensible full-arch plan actually contains (cantilever arithmetic, occlusal scheme, parafunction screening, immediate-load versus delayed-load decisions), see the zirconia full-arch review and the All-on-4 patient reference. For the clinic-level worked example of what the maximalist-plan failure mode produces in returned cases, see the Metal Dental Clinic, Da Nang review. For the broader decision framework on when overseas dental implant treatment is and is not the right call, see the long read on when to go overseas for dental treatment. For the same over-prescription dynamic applied to a different procedure category (asymptomatic third-molar extraction, the 2020 Cochrane evidence that the prophylactic recommendation does not survive, and the upselling pattern that adds wisdom-tooth extraction to international dental tourism plans on the “while you are already here” rationale) see the review of when extracting wisdom teeth is the wrong answer.